"Separating contenders from
pretenders in breast cancer"

-- ASCO Post

"Blazes a trail in breast cancer"

-- Nature Biotechnology

"A glimpse into the future of
phase II drug development?"

-- NEJM

I-SPY Email List Sign-up

Featured News

KEYTRUDA’s Recent Success in Triple-Negative Breast Cancer Validates I-SPY 2 Adaptive Platform Approach to Phase II Clinical Trials KEYTRUDA’s Recent Success in Triple-Negative Breast Cancer Validates I-SPY 2 Adaptive Platform Approach to Phase II Clinical Trials

Keytruda's recent success in TN breast cancer predicted by I-SPY2 results

Press Release

August 6, 2019

Genomic Testing in Breast Cancer May Enhance Personalized Treatment: Update of I-SPY 2 Genomic Testing in Breast Cancer May Enhance Personalized Treatment: Update of I-SPY 2

I-SPY in the News

November 28, 2018

I-SPY2 Presentations and Posters at SABCS 2018 I-SPY2 Presentations and Posters at SABCS 2018

Come see what I-SPY has been up to at the 2018 San Antonio Breast Cancer Symposium

News Update

November 22, 2018

-- more news --

What is I-SPY?

The I-SPY series of trials are changing the way new treatments are developed for breast cancer, helping make available new, better and more personalized treatments, faster. At the heart of the I-SPY program is the ground-breaking I-SPY 2 platform trial for neoadjuvant treatment of locally advanced breast cancer.